Navigation Links
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Date:5/24/2010

macodynamic response of various biomarkers in peripheral blood to RG2833.  RG2833 is a new chemical entity, which is the subject of a composition of matter patent application, which if allowed, will remain in force until 2029 prior to any patent term extensions.  RG2833 has been developed in collaboration with scientists from The Scripps Research Institute and a broad network of international scientific thought leaders.  Repligen's research efforts have been partially funded with grants from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Alliance, GoFAR and the National Ataxia Foundation.  We are also evaluating HDAC-3 inhibitors in animal models of Huntington's disease and cognition.

About Friedreich's Ataxia

Friedreich's ataxia is an inherited neurodegenerative disease caused by a single gene defect that results in inadequate production of the protein frataxin.  Low levels of frataxin lead to degeneration of both the nerves controlling muscle movements in the arms and legs and the nerve tissue in the spinal cord.  Symptoms of Friedreich's ataxia typically emerge between the ages of five and fifteen and often progress to severe disability, incapacitation or loss of life in early adulthood.  Preclinical studies have shown that specific HDAC inhibitors increase production of the protein frataxin, and may have the potential to arrest disease progression in patients with Friedreich's ataxia.  At present, there are no effective treatments for Friedreich's ataxia.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  In addition, we are the world's leading supplier of recombinant Protein A, the sales of w
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)...   Medfusion, Inc., a patient engagement ... and patients, today announced a $3 million investment ... venture capital firms.   "We welcome ... City Venture Partners and Hatteras Venture Partners," said ... Chairman. "Both firms, experience working at the intersection ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of a groundbreaking new version of its flagship DNA design ... methodology breaks down complex DNA sequences into numerous genetic parts, which in turn ...
(Date:8/31/2015)... ... 31, 2015 , ... In recent years, biodegradable plastics have ... carbon footprints and compostability. These properties can help in limiting the degradation of ... of applications, the market for biodegradable plastics can be broadly segmented into packaging, ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.19 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology Technology:Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... ... Solutions to Complex Localization Needs , ... Beijing, China (PRWEB) June 26, 2009 -- CSOFT International Ltd., a leading ... global market, announced the upcoming launch of L10NPRO 3.0 at its 6th Annual Worldwide Operations ...
... - Guidelines Specify that Validated Molecular Assays Should be Considered ... Benefit - , , GENEVA, and REDWOOD CITY, Calif., ... ) today reported that the St. Gallen International Consensus Panel ... the first time that validated multigene assays, such as Onco ...
... Reinstates Booster Dose of Hib Vaccine - , , ... the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), ... supply of its Hib-containing vaccines to enable the return to a ... increased supply, on July 1, the U.S. Centers for Disease Control ...
Cached Biology Technology:CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 2CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 3CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 4CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 5Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer 2Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer 3Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer 4Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer 5Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply 2Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply 3Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply 4Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply 5Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply 6
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... years ago, mammalian target of rapamycin or mTOR, a ... the antidepressant effects of ketamine, the first rapidly acting ... later, a group at the National Institutes of Mental ... receptor antagonist, also produced rapidly appearing antidepressant effects, similar ...
... crop production systems to protect crops from radiation, wind, ... the United States Department of Agriculture, 43% of floricultural ... or other temporary cover. Although black nets are most ... white "dispersive" netting in order to determine effects of ...
... growth and reproduction of all organisms. In plants, zinc plays ... photosynthesis, and sugar and starch synthesis. Apple, one of the ... zinc deficiency. A new study in HortTechnology recommends ... apple trees in order to enhance fruit quality. ...
Cached Biology News:mTOR: A key brain signaling mechanism for rapidly acting antidepressants 2Shadehouses with photoselective nets featured in study of growing conditions 2Zinc sulfate, sugar alcohol zinc sprays improve apple quality 2